Vilar Lab
Eduardo Vilar, M.D., Ph.D.
Principal Investigator
Research Areas
- Colorectal Cancer
- Hereditary Cancer Syndrome
The Vilar Lab has contributed to the characterization of the genomic and transcriptomic landscape of colorectal premalignancy by both using next-generation sequencing and systems biology tools, which has allowed us to identify new genes cooperating in carcinogenesis (such as CNOT3), and also identifying novel drug targets for clinical trial implementation (such as Naproxen, neoantigens for vaccines). The team has also participated in the development of ex vivo models to better recapitulate the biology of the uninvolved adjacent mucosa and premalignancy.
, is professor and chair ad interim of Clinical Cancer Prevention and is a physician-scientist and medical oncologist by training. His clinical expertise and practice are devoted to the care of patients and families diagnosed with hereditary cancer syndromes with a special emphasis in Lynch Syndrome and familial adenomatous polyposis. Dr. Vilar's long term goal is to contribute to the understanding of colorectal cancer carcinogenesis at the molecular and cellular level and leverage this information to develop novel cancer interception strategies for these genetic conditions.
Dr. Vilar has designed investigator-initiated clinical trials in Lynch Syndrome that have been funded by the National Cancer Institute through the N01 (now UG1) Chemoprevention Consortium for early drug development in prevention.
Dr. Vilar is a regular member of the Graduate School of Biomedical Sciences in the Cancer Biology and Quantitative Science programs. He is on X (Twitter) at .
The Vilar Lab is funded through multiple mechanisms, such as NIH/NCI (R01, R21, U01, Spore), foundations (SWOG Hope) and generous philanthropic gifts (such as the Feinberg Family Find for Lynch Syndrome research).
The Vilar Laboratory is constantly seeking highly-motivated trainees to work with us at the pre-doctoral and postdoctoral level. Please contact us if interested.